Journal of Cancer Research and Therapeutics Close
 

Figure 4: Network graphs of Check Point Inhibitors and their effect on survival at 2nd line in Nonsmall cell lung cancer. (a) Check point inhibitors and their effect on overall survival at 2nd line, (b) Check point inhibitors and their effect on progression-free survival at 2nd line (Che=Chemotherapy, Niv=Nivolumab, Pem=Pembrolizumab, Pem (h)=Pembrolizumab high dose; 10 mg/kg, Ate=Atezolizumab, Ave=Avelumab)

Figure 4: Network graphs of Check Point Inhibitors and their effect on survival at 2<sup>nd</sup> line in Nonsmall cell lung cancer. (a) Check point inhibitors and their effect on overall survival at 2<sup>nd</sup> line, (b) Check point inhibitors and their effect on progression-free survival at 2<sup>nd</sup> line (Che=Chemotherapy, Niv=Nivolumab, Pem=Pembrolizumab, Pem (h)=Pembrolizumab high dose; 10 mg/kg, Ate=Atezolizumab, Ave=Avelumab)